Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions

Dr Awan on Psoriasis (September 2026)

Dr Awan on Psoriasis (September 2026)

Dr Lewitt on Psoriasis (September 2026)

Dr Lewitt on Psoriasis (September 2026)

How do you discuss infection-related concerns with patients who may be hesitant about starting tildrakizumab?

Sep 4, 2026Psoriasis

How do you discuss infection-related concerns with patients who may be hesitant about starting tildrakizumab?

-

What have you learned from patients who have remained on tildrakizumab long term?

Sep 4, 2026Psoriasis

What have you learned from patients who have remained on tildrakizumab long term?

-

When you're evaluating a medically complex patient with psoriasis, where does tildrakizumab fit into your treatment decision-making?

Sep 4, 2026Psoriasis

When you're evaluating a medically complex patient with psoriasis, where does tildrakizumab fit into your treatment decision-making?

-

How have conversations with oncologists or other specialists influenced your approach to treating psoriasis in patients with a history of malignancy?

Sep 4, 2026Psoriasis

How have conversations with oncologists or other specialists influenced your approach to treating psoriasis in patients with a history of malignancy?

-

What role does long-term safety experience play when you're choosing among multiple appropriate biologic options?

Sep 4, 2026Psoriasis

What role does long-term safety experience play when you're choosing among multiple appropriate biologic options?

-

Are there patients you consider medically complex who might not fit the traditional definition?

Sep 4, 2026Psoriasis

Are there patients you consider medically complex who might not fit the traditional definition?

-

How do you decide when a chronic disease is well controlled enough versus when additional improvement should still be pursued?

Sep 1, 2026Psoriasis

How do you decide when a chronic disease is well controlled enough versus when additional improvement should still be pursued?

-

When patients and clinicians define treatment success for psoriasis differently, how do you navigate those conversations?

Sep 1, 2026Psoriasis

When patients and clinicians define treatment success for psoriasis differently, how do you navigate those conversations?

-

Have you found that patient satisfaction and clinical response always align when evaluating treatment success with apremilast?

Sep 1, 2026Psoriasis

Have you found that patient satisfaction and clinical response always align when evaluating treatment success with apremilast?

-

What factors make you comfortable continuing apremilast in a patient who has improved but not achieved complete clearance?

Sep 1, 2026Psoriasis

What factors make you comfortable continuing apremilast in a patient who has improved but not achieved complete clearance?

-

How do you determine whether a patient is benefiting enough from apremilast to continue therapy rather than pursue a different option?

Sep 1, 2026Psoriasis

How do you determine whether a patient is benefiting enough from apremilast to continue therapy rather than pursue a different option?

-

Are there patients who technically qualify for more aggressive therapy but whom you still consider for apremilast? Why?

Sep 1, 2026Psoriasis

Are there patients who technically qualify for more aggressive therapy but whom you still consider for apremilast? Why?

-

What misconceptions do patients commonly have about field therapy before they ever begin treatment?

Aug 7, 2026Actinic Keratosis

What misconceptions do patients commonly have about field therapy before they ever begin treatment?

-

How do you decide when a patient should transition from lesion-directed treatment to field therapy?

Aug 7, 2026Actinic Keratosis

How do you decide when a patient should transition from lesion-directed treatment to field therapy?

-

What should clinicians know about ordering tirbanibulin in the EMR to avoid confusion regarding quantity or packet selection?

Aug 7, 2026Actinic Keratosis

What should clinicians know about ordering tirbanibulin in the EMR to avoid confusion regarding quantity or packet selection?

-

What misconceptions do patients sometimes have about evaluating response after tirbanibulin treatment?

Aug 7, 2026Actinic Keratosis

What misconceptions do patients sometimes have about evaluating response after tirbanibulin treatment?

-

Before starting tirbanibulin, what do you tell patients about the overall treatment timeline, including when they should expect you to evaluate the results?

Aug 7, 2026Actinic Keratosis

Before starting tirbanibulin, what do you tell patients about the overall treatment timeline, including when they should expect you to evaluate the results?

-

Can you describe a patient scenario in which tirbanibulin allowed you to move forward with field therapy during the summer rather than delaying treatment until a different season?

Aug 7, 2026Actinic Keratosis

Can you describe a patient scenario in which tirbanibulin allowed you to move forward with field therapy during the summer rather than delaying treatment until a different season?

-

What do dermatologists sometimes overlook about apremilast when evaluating today’s treatment options?

Aug 3, 2026Psoriasis

What do dermatologists sometimes overlook about apremilast when evaluating today’s treatment options?

-

Which patients tend to surprise you with how well they do on apremilast?

Aug 3, 2026Psoriasis

Which patients tend to surprise you with how well they do on apremilast?

-

In what situations do you use apremilast alongside other psoriasis therapies?

Aug 3, 2026Psoriasis

In what situations do you use apremilast alongside other psoriasis therapies?

-

What has real-world experience taught us about apremilast that clinical trials alone could not?

Aug 3, 2026Psoriasis

What has real-world experience taught us about apremilast that clinical trials alone could not?

-

How do patient-defined treatment goals differ from clinician-defined treatment goals?

Aug 3, 2026Psoriasis

How do patient-defined treatment goals differ from clinician-defined treatment goals?

-

What aspects of living with psoriasis do clinicians sometimes underestimate?

Aug 3, 2026Psoriasis

What aspects of living with psoriasis do clinicians sometimes underestimate?

-